NKR16_PICO9_Tramadol for Fibromyalgia

Characteristics of studies

Characteristics of included studies

Bennett 2003

Methods	
Participants	
Interventions	
Outcomes	
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Russell 2000

Methods	
Participants	
Interventions	
Outcomes	
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Footnotes

Characteristics of excluded studies

Footnotes

Characteristics of studies awaiting classification

Footnotes

Characteristics of ongoing studies

Footnotes

Summary of findings tables

Additional tables

References to studies

Included studies

Bennett 2003

[Empty]

Russell 2000

[Empty]

Excluded studies

Studies awaiting classification

Ongoing studies

Other references

Additional references

Other published versions of this review

Classification pending references

Data and analyses

1 Tramadol versus placebo

| Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
1.1 Dropout due to adverse events	1	315	Risk Ratio (M-H, Fixed, 95% CI)	1.60 [0.93, 2.76]
1.2 Constipation	1	312	Risk Ratio (M-H, Fixed, 95% CI)	3.00 [1.12, 8.05]
1.3 Nausea	1	312	Risk Ratio (M-H, Random, 95% CI)	1.72 [1.01, 2.95]
1.4 Dizziness	1	312	Risk Ratio (M-H, Fixed, 95% CI)	1.88 [0.82, 4.30]
1.5 Somnolence	1	312	Odds Ratio (M-H, Fixed, 95% CI)	2.10 [0.82, 5.35]

Figures

Figure 1 (Analysis 1.1)

Forest plot of comparison: 1 Tramadol versus placebo, outcome: 1.1 Dropout due to adverse events.

Figure 2 (Analysis 1.2)

Forest plot of comparison: 1 Tramadol versus placebo, outcome: 1.2 Constipation.

Figure 3 (Analysis 1.3)

Forest plot of comparison: 1 Tramadol versus placebo, outcome: 1.3 Nausea.

Figure 4 (Analysis 1.4)

Study or Subgroup	Tramadol Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Bennett 2003	15	156	8	156	100.0%	1.88 [0.82, 4.30]
Total (95% CI)		**156**		**156**	**100.0%**	**1.88 [0.82, 4.30]**
Total events	15		8			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.49 (P = 0.14)

Risk Ratio M-H, Fixed, 95% CI — scale 0.01 0.1 1 10 100 — Favours Tramadol Favours Placebo

Forest plot of comparison: 1 Tramadol versus placebo, outcome: 1.4 Dizziness.

Figure 5 (Analysis 1.5)

Study or Subgroup	Tramadol Events	Total	Control Events	Total	Weight	Odds Ratio M-H, Fixed, 95% CI
Bennett 2003	14	156	7	156	100.0%	2.10 [0.82, 5.35]
Total (95% CI)		**156**		**156**	**100.0%**	**2.10 [0.82, 5.35]**
Total events	14		7			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.55 (P = 0.12)

Odds Ratio M-H, Fixed, 95% CI — scale 0.01 0.1 1 10 100 — Favours [experimental] Favours [control]

Forest plot of comparison: 1 Tramadol versus placebo, outcome: 1.5 Somnolence.

Figure 4 (Analysis 1.4)

Study or Subgroup	Tramadol Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI